DTC Genomics Firms Say They Want to Comply with FDA Regs but Maintain Direct Access

At an advisory committee meeting held this week to discuss how FDA should regulate DTC genomics firms, several companies said that they are willing to meet the agency's clinical and analytical validity requirements, but will push to maintain direct-to-consumer marketing for their products.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.